Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. [electronic resource]
Producer: 20000828Description: 791-8 p. digitalISSN:- 0100-879X
- Adolescent
- Adult
- Amifostine -- adverse effects
- Antineoplastic Agents, Alkylating -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Cytoprotection -- drug effects
- Feasibility Studies
- Female
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Radiation-Protective Agents -- adverse effects
- Statistics, Nonparametric
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.